ArticleEpidemiology and infection2022
Burden of multidrug and extensively drug-resistant ESKAPEE pathogens in a secondary hospital care setting in Greece.
Article in Epidemiology and infection, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Prevalence, resistance profile of ESKAPEE pathogens, and molecular detection of PMQR-associated genes among Levofloxacin-resistant gram-negative ESKAPEE isolates from critically-ill patients.BMC infectious diseases · 2026Article
- Evolution of Antimicrobial Resistance inMicroorganisms · 2026Review
- Assessing the public health risk from ESKAPE pathogens including MRSA and VRE on high-touch shopping cart surfaces.AIMS public health · 2026Review
- Article
- Carbapenem-ResistantMicroorganisms · 2025Review
- Outcome of Bloodstream Infections Caused by Antibiotic-Resistant Bacteria: A 7-Year Retrospective Study at the University Hospital of Palermo, Italy.Antibiotics (Basel, Switzerland) · 2025Article
- Antimicrobial Resistance in ESKAPE Pathogens: A Retrospective Epidemiological Study at the University Hospital of Palermo, Italy.Antibiotics (Basel, Switzerland) · 2025Article
- Detection of Delafloxacin Resistance Mechanisms in Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2025Article
- In-hospital mortality from healthcare-associated infection by multidrug-resistant Pseudomonas aeruginosa: a competing risks analysis of a 4-year propensity-matched cohort study in southern China.GMS hygiene and infection control · 2025Article
- COVID-19 pandemic increased ESKAPEEc bloodstream infections and amplified carbapenem resistance in Chinese children: a multicenter surveillance study (2016-2023).Frontiers in cellular and infection microbiology · 2025Article
- PHIStruct: improving phage-host interaction prediction at low sequence similarity settings using structure-aware protein embeddings.Bioinformatics (Oxford, England) · 2024Article
- Overview of Antimicrobial Resistant ESKAPEE Pathogens in Food Sources and Their Implications from a One Health Perspective.Microorganisms · 2024Review
- An ensemble deep learning model for predicting minimum inhibitory concentrations of antimicrobial peptides against pathogenic bacteria.iScience · 2024Article
- Article
- Clinical burden of community-associated infections caused by multidrug-resistant Pseudomonas aeruginosa: a propensity-matched longitudinal cohort study in Southern China.GMS hygiene and infection control · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bacterial antibiotic resistance (AMR) is a significant threat to public health, with the sentinel 'ESKAPEE' pathogens, being of particular concern. A cohort study spanning 5.5 years (2016-2021) was conducted at a provincial general hospital in Crete, Greece, to describe the epidemiology of ESKAPEE-associated bacteraemia regarding levels of AMR and their impact on patient outcomes. In total, 239 bloodstream isolates were examined from 226 patients (0.7% of 32 996 admissions) with a median age of 75 years, 28% of whom had severe comorbidity and 46% with prior stay in ICU. Multidrug resistance (MDR) was lowest for
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.